Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/20/2024 | Press release | Distributed by Public on 09/20/2024 07:29
Please select the service you want to use:
Smartlinks | BKV Corporation | Finance | Stock Markets | Security Markets | Stock Markets | Security Markets | Company News | Top Company News | IPO | Oil and Gas | Investment Funds | Private Companies | Oil and Gas Exploration and Production Companies
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact